CD274 and nasopharyngeal carcinoma: In the KEYNOTE-028 multicohort phase 1b trial study, pembrolizumab monotherapy, a monoclonal antibody specific for PD-L1, was evaluated in a cohort of NPC patients (n=27) with PD-L1 positive, recurrent or metastatic NPC.